Publikationen, an denen er mitarbeitet Antonio Rivero Juárez (24)

2021

  1. Cd46 genetic variability and hiv-1 infection susceptibility

    Cells, Vol. 10, Núm. 11

2019

  1. A Knockout IFNL4 Variant Is Associated with Protection from Sexually Transmitted HIV-1 Infection

    Journal of Infectious Diseases, Vol. 219, Núm. 5, pp. 772-776

  2. Genetic associations of the vitamin D and antiviral pathways with natural resistance to HIV-1 infection are influenced by interpopulation variability

    Infection, Genetics and Evolution, Vol. 73, pp. 276-286

  3. Genetic markers of lipid metabolism genes associated with low susceptibility to HCV infection

    Scientific Reports, Vol. 9, Núm. 1

2015

  1. Association of complement receptor 2 polymorphisms with innate resistance to HIV-1 infection

    Genes and Immunity, Vol. 16, Núm. 2, pp. 134-141

  2. IFNL4 rs368234815 polymorphism is associated with innate resistance to HIV-1 infection

    AIDS

  3. Longitudinal evaluation of hepatitis C viral persistence in HIV-infected patients with spontaneous hepatitis C clearance

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 34, Núm. 11, pp. 2171-2175

2014

  1. A polymorphism linked to RRAS, SCAF1, IRF3 and BCL2L12 genes is associated with cirrhosis in hepatitis C virus carriers

    Liver International, Vol. 34, Núm. 4, pp. 558-566

  2. A regulatory polymorphism in HAVCR2 modulates susceptibility to HIV-1 infection

    PLoS ONE, Vol. 9, Núm. 9

  3. Association of low-density lipoprotein receptor genotypes with hepatitis C viral load

    Genes and Immunity, Vol. 15, Núm. 1, pp. 16-24

  4. Evolutionary analysis identifies an MX2 haplotype associated with natural resistance to HIV-1 infection

    Molecular Biology and Evolution, Vol. 31, Núm. 9, pp. 2402-2414

  5. IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against hepatitis C virus genotype 1 or 4 in Caucasians

    PLoS ONE, Vol. 9, Núm. 4

2013

  1. Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV

    Infection, Vol. 41, Núm. 1, pp. 21-26

  2. Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 32, Núm. 11, pp. 1427-1435

  3. Natural Killer KIR3DS1 Is Closely Associated with HCV Viral Clearance and Sustained Virological Response in HIV/HCV Patients

    PLoS ONE, Vol. 8, Núm. 4

  4. Pegylated interferon plus ribavirin is suboptimal inIL28B CC carriers without rapid response

    Journal of Infection, Vol. 67, Núm. 1, pp. 59-64

  5. Short communication: Atazanavir-based therapy is associated with higher hepatitis C viral load in HIV type 1-infected subjects with untreated hepatitis C

    AIDS Research and Human Retroviruses, Vol. 29, Núm. 2, pp. 223-225

  6. The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylatedinterferon/ ribavirin treatment varies according to hepatitis C virus-1 subtype

    AIDS, Vol. 27, Núm. 12, pp. 1941-1947

  7. Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection

    AIDS, Vol. 27, Núm. 17, pp. 2715-2724

2012

  1. Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4

    Journal of Antimicrobial Chemotherapy, Vol. 67, Núm. 1, pp. 202-205